Inventor · disambiguated record
Robert Kauffman
Also filed as: KAUFFMAN ROBERT · KAUFFMAN ROBERT S
2 granted patents·9 pending applications·0 citations·filing 2004–2024
28Inventor score
Top patents by PatentIndex Score
11 records- 0172US2025041349A1CRISPR-CAS9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells and Uses ThereofVERTEX PHARMA·Filed 2024·Application pending·0 cites
- 0258US12161674B2CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereofVERTEX PHARMA·Filed 2018·Granted Dec 10, 2024·0 cites·16 claims
- 0350US2024158478A1SARS-CoV-2 Antibodies and Fragments, Therapeutic Uses, Diagnostic Uses, and Compositions Related TheretoUNIV EMORY·Filed 2022·Application pending·0 cites
- 0447US2010189688A1Dose forms comprising VX-950 and their dosage regimenVERTEX PHARMA·Filed 2009·Application pending·0 cites
- 0546US2020054633A1Combination therapies for treating influenza virus infectionVERTEX PHARMA·Filed 2019·Application pending·0 cites
- 0640US2007225339A1Compositions and methods for treating rheumatoid arthritisMOHANLAL RAMON·Filed 2007·Application pending·0 cites
- 0738US8871812B2Therapeutic regimen comprising PEG-interferon, ribavirin and VX-950 for the treatment of hepatitisVERTEX PHARMA·Filed 2012·Granted Oct 28, 2014·0 cites·26 claims
- 0838US2005112093A1Combination therapy for HCV infectionFiled 2004·Application pending·0 cites
- 0935US2011165119A1Telaprevir dosing regimenBEUMONT MARIA GLORIA·Filed 2009·Application pending·0 cites
- 1029US2011236351A1Therapeutic Regimen Comprising PEG-Interferon, Ribavirin and VX-950 for the Treatment of HepatitisVERTEX PHARMA·Filed 2011·Application pending·0 cites
- 1119US2012039850A1HCV Combination Therapies Comprising Pegylated Interferon, Ribavirin and TelaprevirMCNAIR LINDSAY·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert Kauffman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →